PureTech

On #RareDiseaseDay, the world recognizes & supports those living w/ #rarediseases. At PureTech, this is our focus every day. Today, our team joined @Cycle4Survival to champion rare cancer research – an extension of our work at Gallop Oncology to advance LYT-200 in #AML. The same commitment drives our team at Celea Therapeutics to advance deupirfenidone for pp w/ #IPF. Both programs received Orphan Drug Designation, reflecting the need in these communities & what drives us to deliver on our mission .

Our CEO, Robert Lyne, and Co-founder & President, Eric Elenko, PhD, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT. bit.ly/4azs3Rw

During #RareDiseaseMonth, we’re reminded that innovation matters most where options are few. Today we're proud to share that deupirfenidone has received #OrphanDrugDesignation from the FDA and European Commission for #IPF. Read More: bit.ly/4kSPNne

On #InternationalDayofWomenandGirlsInScience, we’re proud to recognize the women shaping the future of PureTech. From advancing new possibilities in #IPF & #AML, to translating ideas into medicines, they exemplify scientific leadership. By amplifying their voices today, we aim to inspire the next gen of #WomenInSTEM #IDWGS

Our CEO, Robert Lyne, and President, Eric Elenko, presented at #JPM26, outlining PureTech’s strategy, portfolio progress, and priorities for the year ahead. Watch the presentation replay here: bit.ly/3YKFeID

Our CEO, Robert Lyne, will present at #JPM26 on Wednesday, January 14th, at 4:30pm PST / 7:30pm EST bit.ly/4soa0oh

Wishing our colleagues, shareholders, and the patients we serve a warm and joyful holiday season. We look forward to continuing our important work together in 2026!

Today we announced the appointment of Robert Lyne as CEO. Rob brings deep familiarity with our programs, people, and model, and will lead PureTech in building on this strong foundation to advance transformative therapies for patients and create value for shareholders bit.ly/3Y1hkZ6

Today we announced the successful completion of the End-of-Ph2 meeting w/ FDA for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis #IPF. The Ph3 SURPASS-IPF trial is on track to start in 1H26 by our newest Founded Entity, Celea Therapeutics. bit.ly/4a3fE8A

We’re proud to share positive initial topline data from the Ph1b trial of LYT-200 in relapsed/refractory #AML & high-risk #MDS. Our Founded Entity, Gallop Oncology, will present additional details tomorrow at #ASH25 bit.ly/3XzOjU7

Happy Thanksgiving from all of us at PureTech!

New data from our Phase 1b trial of LYT-200 in #AML will be presented at #ASH25. Results to date show strong clinical activity + favorable safety in heavily pretreated patients. Matured data to come at ASH & in Q4 2025 bit.ly/4nDvqKt

New analyses presented at #CHEST2025 demonstrate deupirfenidone’s consistent safety & efficacy in people living w/ #IPF, regardless of age. We’re proud to showcase the potential for deupirfenidone to change the treatment paradigm for people w/ IPF bit.ly/4ndhOFr

We’re proud to share new data at #ERS2025 from our Phase 2b ELEVATE IPF OLE. The data show that patients w/ #IPF who switched from placebo or pirfenidone to deupirfenidone achieved lung function stabilization w/ favorable tolerability. #ERSCongress @EuroRespSoc bit.ly/42VtcOS

Our team is proud to participate in the Pulmonary Fibrosis Foundation’s National Walk Day in honor of the passionate community driving advances in idiopathic pulmonary fibrosis (#IPF) care: patients, caregivers, physicians, advocates, and researchers working to develop new medicines. This year feels especially meaningful given the advances we’ve made with deupirfenidone and the important milestones ahead as we prepare for Phase 3. Together, we are moving research forward to deliver better options for patients. @PFFORG #PFFWalk #GivingLifeToScience

Congrats to our Founded Entity @SeaportTx on advancing its second candidate into the clinic!

Today we announced our 2025 Half-Year results & will host a webcast at 9am EDT/2pm BST. We continue to give life to science while transforming innovation into value through our hub-and-spoke model. Read more: bit.ly/41ulOJQ

At the 2025 IPF Summit, PureTech showcased how we’re pairing compelling data with deep patient insights and innovative trial design to advance deupirfenidone (LYT-100) as a potential new standard of care in #idiopathicpulmonaryfibrosis. From the strength of our Phase 2b ELEVATE IPF data to new research highlighting how patients weigh efficacy vs. tolerability, we believe we’re setting a new bar for late-stage development in this field. Under the stewardship of our newly launched Founded Entity, Celea Therapeutics, deupirfenidone is poised to deliver meaningful outcomes for people living with #IPF bit.ly/4ndDVfB

We’re proud to announce the launch of Celea Therapeutics, a new PureTech Founded Entity dedicated to transforming the treatment of serious respiratory diseases. Celea’s lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the potential to set a new standard of care for #idiopathicpulmonaryfibrosis #IPF and other fibrotic lung diseases. Led by Sven Dethlefs, PhD, former CEO of Teva North America, Celea reflects our commitment to advancing differentiated programs through focused, capital-efficient structures with seasoned leadership. bit.ly/3Upp5pS